This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-2861v1 69/10/4270    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jäger, M. Articles by Lindhofer, H. Search for Related Content PubMed PubMed Citation Articles by Jäger, M. Articles by Lindhofer, H.

The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2

¹ TRION Research GmbH, Martinsried, Germany and ² TRION Pharma GmbH, Munich, Germany

Requests for reprints: Horst Lindhofer, TRION Pharma GmbH, Frankfurter Ring 193a, 80807 Munich, Germany. Phone: 49-89-324266100; Fax: 49-89-324266199; E-mail: horst.lindhofer{at}trionpharma.de.

Key Words: HER2/neu low expression • trifunctional antibody • ertumaxomab • immunomodulation • tumor antigens

Human epidermal growth factor receptor 2 (HER2/neu) is an important target for the treatment of the breast cancers in which it is overexpressed. However, no approved anti-HER2/neu therapy is available for the majority of breast cancer patients, who express HER2/neu at low levels (with scores of 1+ or 2+/fluorescence in situ hybridization–negative). The trifunctional antibody ertumaxomab targets HER2/neu, CD3, and activating Fc receptors. In presence of ertumaxomab, tri-cell complexes consisting of tumor cells, T cells, and accessory cells form to cause tumor cell lysis. In a phase I trial with metastatic breast cancer patients, ertumaxomab could be applied safely and resulted in radiographically confirmed clinical responses. In this study, we compare ertumaxomab- and trastuzumab-mediated killing of cancer cell lines that express HER2/neu at low and high levels. Under optimal conditions for trastuzumab-mediated destruction of HER2/neu-overexpressing cells, only ertumaxomab was able to mediate the elimination of tumor cell lines that express HER2/neu at low levels (1+). Ertumaxomab-mediated activity was accompanied by a Th1-based cytokine release, a unique mode of action of trifunctional antibodies. Competitive binding studies with trastuzumab and 520C9 mapped the binding site of ertumaxomab to the extracellular regions II and III of the HER2/neu ectodomain. This site is distinct from the binding site of trastuzumab, so that HER2/neu-expressing tumor cells can be eliminated by ertumaxomab in the presence of high amounts of trastuzumab. The ability of ertumaxomab to induce cytotoxicity against various tumor cell lines, including those with low HER2/neu antigen density, may provide a novel therapeutic option for breast cancer patients who are not eligible for trastuzumab treatment. [Cancer Res 2009;69(10):4270–6]